MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]

MLA

Aaron, Gerds, et al. “MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM].” Clinical Lymphoma Myeloma and Leukemia, vol. 22, Oct. 2022, p. S340. EBSCOhost, https://doi.org/10.1016/s2152-2650(22)01464-1.

APA

Aaron, G., Srdan, V., Alessandro, V., Haifa Kathrin, A.-A., David, L., Andrew, K., Sebastian, G., Alessandra, I., Yeow Tee, G., Mihaela, L., Miklos, E., Maria Laura, F., Donal, M., Andrew, P., Sung-Soo, Y., Vikas, G., Jean-Jacques, K., Rafe, D., Jun, K., & Ruben, M. (2022). MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]. Clinical Lymphoma Myeloma and Leukemia, 22, S340. https://doi.org/10.1016/s2152-2650(22)01464-1

Chicago

Aaron, Gerds, Verstovsek Srdan, Vannucchi Alessandro, Al-Ali Haifa Kathrin, Lavie David, Kuykendall Andrew, Grosicki Sebastian, et al. 2022. “MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM].” Clinical Lymphoma Myeloma and Leukemia 22 (October): S340. doi:10.1016/s2152-2650(22)01464-1.